The landmark deal means young people with a form of leukaemia are set to receive CAR-T (a chimeric antigen receptor T-cell) therapy within weeks. It represents one of the fastest funding approvals in the 70 year history of the NHS. Unlike other forms of treatment, CAR-T therapy is specifically developed for each individual patient and involves reprogramming the patient’s own immune system cells which are then used to target their cancer
Read more here:
568 total views, 2 views today
Leave a Reply